MAP3K5 and metabolic dysfunction-associated steatohepatitis: Selonsertib (GS-4997), a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with anti-inflammatory and anti-fibrotic properties, demonstrated a potential role in reducing fibrosis in NASH and stage 2–3 fibrosis [282]; it is now being tested in stage 3 fibrosis and compensated cirrhotic NASH patients (STELLAR3 study ClinicalTrials.gov: NCT03053050 and STELLAR4 study ClinicalTrials.gov: NCT03053063).